Assessment of Early-detection Based on Liquid Biopsy in Lung Cancer (ASCEND-LUNG)

Inclusion Criteria: * Signed informed consent * Male or female, age equal to or greater than 40 years old and less than 75 years old * Blood sample was collected before surgery for the detection of cfDNA methylation and other biomarkers * Lung cancer patients diagnosed for the first time within 42 days before blood sampling without any anti-tumor treatment; or patients who are highly suspected of lung cancer through imaging evaluation or other routine clinical diagnosis and confirmed by tissue biopsy or surgical specimens within 42 days after blood sampling * The subject has not received any local or systemic anti-tumor therapy before blood collection, including (not limited to) any surgery, local or systemic radiotherapy and chemotherapy, targeted therapy (including anti-angiogenesis), immunotherapy, cancer vaccines and hormone therapy, etc. Exclusion Criteria: * Unable to obtain sufficient and qualified blood samples * Female subjects who are pregnant or breastfeeding * Patients who have received organ transplantation or non-autologous bone marrow or stem cell transplantation * Patients who have received blood transfusion within 7 days before blood sampling * Patients who have received anti-infection treatment within 14 days before blood collection * Patients who have receiving anti-tumor drugs for other diseases within 30 days before blood collection, such as methotrexate, cyclophosphamide, mercaptopurine, chlorambucil, tamoxifen, etc. * Patients who suffered from other malignant tumors or multiple primary tumors at the same time * Pathological confirmed benign lesions by tissue biopsy or surgery * Insufficient sample for a confirmed pathological diagnosis * Lung cancer patients with ground glass nodules on CT imaging.